NutriBand Secures $5M Non-Convertible Credit Line at 7% for AVERSA FDA Approval
NTRB is trading near its 52-week low of $2.9 (12% above the low) on elevated volume (2.8× avg).
Summary
NutriBand has secured an amended three-year, $5 million credit line at 7% interest, which is non-convertible into common stock. This facility replaces a prior credit line set to expire next month and provides crucial funding for the AVERSA fentanyl transdermal system through FDA approval and into commercialization. The financing is material for the company, especially given its recent 10-K and 10-Q filings which highlighted significant net losses and cash burn, and mentioned going concern doubts. This non-dilutive capital infusion helps alleviate immediate liquidity concerns and supports a key product's path to market.
At the time of this announcement, NTRB was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $2.90 to $11.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.